Holen Sie sich die Stockscreener-App
1.98
1.98%
-0.04
Handel nachbörslich:
1.98
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - TradingView
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - The Globe and Mail
RLMD Stock Surges 42% in a Week: Here's What You Should Know - TradingView
Alx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation - TipRanks
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - TradingView
ALX Oncology 2025 Annual Report: Evorpacept Clinical Trials, Pipeline Strategy, and CD47 Blockade Advancements - Minichart
ALX Oncology's (ALXO) Buy Rating Reiterated at HC Wainwright - MarketBeat
ALXO: HC Wainwright Reiterates Buy Rating with Price Target at $4.00 | ALXO Stock News - GuruFocus
ALX 2025 10-K: Net loss $101.7M, EPS $(1.90); operating loss $(104.0)M - TradingView
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study - Finviz
Aug Momentum: What is ALX Oncology Holdings Incs book value per share2026 AllTime Highs & Low Risk High Win Rate Picks - baoquankhu1.vn
Alx Oncology Earnings Call Highlights Biomarker Momentum - TipRanks
ALX Oncology initiated with a Buy at UBS - Yahoo Finance
Aug Retail: Does ALX Oncology Holdings Inc stock have upside surprise potentialWatch List & Consistent Income Trade Ideas - baoquankhu1.vn
ALX Oncology (NASDAQ:ALXO) Coverage Initiated by Analysts at UBS Group - MarketBeat
QURE Stock Crashes 32% in a Week: Here's What You Should Know - Finviz
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - Nasdaq
Mirum Completes Enrollment & Screening in Liver Disease Studies - TradingView
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) - The Globe and Mail
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU - The Globe and Mail
ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update - MarketBeat
Pharma News: Can Piedmont Office Realty Trust Inc grow without external fundingStock Surge & Accurate Intraday Trading Signals - baoquankhu1.vn
ALX Oncology Q4 Earnings Call Highlights - Defense World
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - marketscreener.com
ALXO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones (NASDAQ:ALXO) - Seeking Alpha
Earnings Scheduled For February 27, 2026 - Sahm
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q4 2025 Earnings Call Transcript - Insider Monkey
ALXO's Progress in Clinical Trials and Financial Strength - GuruFocus
ALX Oncology (NASDAQ:ALXO) Posts Earnings Results - MarketBeat
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... By GuruFocus - Investing.com Canada
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... - Yahoo Finance
ALX Oncology Q4 2025 Earnings Call Transcript - MarketBeat
ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
ALX Oncology Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALX Oncology (ALXO) Q4 2025 Earnings Transcript - AOL.com
Earnings call transcript: ALX Oncology Q4 2025 misses EPS forecast, stock dips - Investing.com Canada
ALXO: Evorpacept and ALX2004 advanced with strong efficacy, robust financing, and pivotal data ahead - TradingView
ALXO: Evorpacept and ALX2004 advanced with strong efficacy, robust financing, and pivotal trial readiness - TradingView
ALXO Prepares for Key Clinical Milestones with Evorpacept and AL - GuruFocus
ALX ONCOLOGY ($ALXO) Releases Q4 2025 Earnings - Quiver Quantitative
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
ALX Oncology (NASDAQ: ALXO) raises $150M and extends cash runway to 2028 - Stock Titan
ALXO: Clinical advances and cost controls drive improved financials and extended cash runway - TradingView
ALXO SEC FilingsAlx Oncology Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A Look Ahead: ALX Oncology Holdings's Earnings Forecast - Benzinga
ALX Oncology (ALXO) Projected to Post Quarterly Earnings on Friday - Defense World
ALX Oncology Holdings (ALXO) Price Target Increased by 11.11% to 3.40 - Nasdaq
Is Teva Pharmaceutical Industries (TEVA) Surpassing Other Healthcare Stocks in Performance This Year? - Bitget
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ALX Oncology Holdings Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Will ALX Oncology Holdings Inc stock recover after earnings2025 Support & Resistance & Verified Short-Term Plans - baoquankhu1.vn
ALXO Should I Buy - Intellectia AI
EV Market: Is ALX Oncology Holdings Inc a stock for growth or value investorsEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
ALX Oncology (ALXO) Expected to Announce Earnings on Friday - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Is ALX Oncology Holdings Inc. stock dividend yield sustainable2025 Historical Comparison & Fast Entry and Exit Trade Plans - mfd.ru
ALX Oncology Pursues Multiple Near-Term Catalysts For Two Novel Cancer Treatments - RTTNews
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):